FFP

FFP, Leukocyte Depleted

• obtained by whole blood or aphresis
• <1×10(6) leukocytes/ componnt rapidly frozen to a temp that will maintain the activity of labile coagulation factors
• Bleed time > 15min are not suitable
• Male donors
• Separated from the red cell component asap after venepuncture and rapidly frozen to <-25degrees for greater F8 yoeld
• Components must meet the specified limits for F8 concentration 
• Should be collected from equal numbers of Group O and non-group O donors due to difference in F8
• Transfused through  170–200 µm filter

Labelling

• Fresh Frozen Plasma, Leucocyte Depleted* and volume
• the blood component producer’s name*
• the donation number and, if divided, sub-batch number*
• the ABO group*
• the RhD group stated as positive or negative*
• the date of collection
• the expiry date of the frozen component*
• the temperature of storage
• the blood pack lot number*
• a warning that the component must be used within 4 hours of thawing if maintained at 22 ±2°C, or up to a maximum of 120 hours of thawing if stored at 4 ±2°C, depending on indication
• the name, composition and volume of the anticoagulant.
• Instruction: Always check patient/component compatibility/identity, Inspect pack and contents for signs of deterioration or damage, Risk of adverse reaction/infection, including vCJD

Storage

• Stored at core temperature of <-25degrees for maximum 36months
• Thawed in a waterbath in a vacuum-sealed overwrap bag bet 33-37 degrees, inspect to ensure no cryoppt is visable and container is intact, if to be stored after thawing for >24, use methods that minimise bacterial contamination
• Must not be refrozen after thawing, use within 4h if maintained at  22 ±2°C or up to a maximum of 120 hours if stored at 4 ±2°C
• Pre-thawed FFP out of controlled temp (4C) can be accepted back if out of storage for <30min on only 1 occassion
• Transfusion FFP completed within 4h
• For indications other than unexpected major hemorrhage, the component should be used within 24h of thawing
• Most F8 loss occurs 24h after thawing, other factors – levels >70% after 120h

FFP, Methylene Blue Treated, Leukocyte Depleted

• Made from plasma from country with a low risk of  vCJD
• Whole blood or aphresis from previously tested donor and contains <1 x 10(6) leukocytes, treated with methylene blue and exposure to visable light to inactivate pathogens
• Rapidly frozen after methylene blue treatment to maintain activity of labile coagulation factors
• MBT process reduces the F8 content by 30% when compared to standard FFP
• Methylene blue removal to <0.30umol/l (<30ug/u)

BCSH Guideline 

• All pathogens inactivated systems inactivate pathogens in plasma
• Envelop viruses generally >4 log reduction
• Non-envelop viruses generally variable (hep A, E parvo)
• These pathogens need to be tested
• SD-FFP includes a prior reduction step, decreases protein S and anti-plasmin but not others 
• If RhD+ plasma is given to RhD- patients – no need to screen for hemolysis and anti-D prophylaxis (RBC content very low)